458 completed, 141 terminated, 112 recruiting, 79 unknown. 917 Phase 1, 276 Phase 2.
Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) LP-118 - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Wake Forest University Health Sciences | 26 | 2026-12-01 | 2026-10-29 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) TSLPR-CART, Cyclophosphamide, Fludarabine - B-All, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2026-11-08 | 2026-11-03 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation QUAIL-100 - Acute Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | Laguna Biotherapeutics, Inc. | 12 | 2026-08-01 | 2026-08-21 |
| Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies Thiotepa, Fludarabine, Busulfan - Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | Sawa Ito, MD | 48 | 2026-07-27 | 2026-08-18 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
Showing 20 of 917. Sign in to see all of them.
Leukemia, Myeloid, Acute (364) · Lymphoma, Non-Hodgkin (300) · Leukemia, Lymphocytic, Chronic, B-Cell (299) · Burkitt Lymphoma (264) · Leukemia (256) · Lymphoma, Large B-Cell, Diffuse (243) · Lymphoma, Mantle-Cell (228) · Lymphoma, Follicular (225) · Lymphoma (217) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (213) · Myelodysplastic Syndromes (197) · Lymphoma, B-Cell, Marginal Zone (194) · Hodgkin Disease (192) · Lymphoma, Large-Cell, Immunoblastic (192)
Hemic and Lymphatic Diseases (917) · Hematologic Diseases (914) · Immunoproliferative Disorders (914) · Lymphatic Diseases (914) · Neoplasms by Histologic Type (914) · Immune System Diseases (912) · Leukemia, Lymphoid (908) · Lymphoproliferative Disorders (904) · Neoplasms (884) · Leukemia (661) · Pathological Conditions, Signs and Symptoms (520) · Pathologic Processes (519) · Disease Attributes (508) · Chronic Disease (432) · Leukemia, Myeloid (417)
Cyclophosphamide (126) · fludarabine phosphate (75) · Cytarabine (73) · fludarabine (69) · Dexamethasone (53) · Vincristine (51) · Methotrexate (50) · Peripheral Blood Stem Cell Transplantation (46) · Filgrastim (44) · Etoposide (40) · Rituximab (34) · Clofarabine (29) · Doxorubicin (29) · Mycophenolic Acid (29) · Melphalan (28)
National Cancer Institute (NCI) (113) · M.D. Anderson Cancer Center (41) · Fred Hutchinson Cancer Center (30) · City of Hope Medical Center (24) · Memorial Sloan Kettering Cancer Center (22) · St. Jude Children's Research Hospital (18) · Therapeutic Advances in Childhood Leukemia Consortium (15) · Masonic Cancer Center, University of Minnesota (14) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14) · Baylor College of Medicine (13) · National Institutes of Health Clinical Center (CC) (12) · Novartis Pharmaceuticals (12) · Children's Oncology Group (10) · Northwestern University (10) · Case Comprehensive Cancer Center (9)
United States (670) · China (95) · Canada (57) · Italy (39) · France (38) · Germany (38) · Australia (35) · Spain (32) · United Kingdom (32) · Netherlands (28) · Israel (16) · Japan (16) · Switzerland (14) · South Korea (13) · Austria (12)
Brenda Sandmaier (6) · Mario Sznol, MD (5) · Jae Park, MD (4) · Jorge Cortes, MD (4) · Judith E. Karp, MD (4) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Steven Grant, MD (4) · Ajay Gopal (3) · Ann E. Woolfrey, MD (3)
PMID 41671463, PMID 34515338, PMID 28054442, PMID 32499241, PMID 40195173, PMID 19949018, PMID 20028764, PMID 22002018, PMID 33741715, PMID 34267079, PMID 34687939, PMID 34889384, PMID 35622074, PMID 35799791, PMID 36858787, PMID 37486616, PMID 39368878, PMID 40233328, PMID 41429239, PMID 10552943, PMID 10632319, PMID 10764422, PMID 11410496, PMID 11756154, PMID 11896112, PMID 12114413, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15231574, PMID 15466934, PMID 15570084, PMID 16135477, PMID 16278404, PMID 16533779, PMID 16564913, PMID 16775234, PMID 16775235, PMID 17020988, PMID 17119113, PMID 17312328, PMID 17562873, PMID 17640728, PMID 17715389, PMID 17947483, PMID 17959855, PMID 17971589, PMID 18048643, PMID 18299450
P30CA033572 (17), P30CA015704 (13), P30CA006973 (11), U01CA070095 (11), U01CA097452 (11), U01CA062461 (9), U01CA069912 (9), U01CA062491 (8), P30CA015083 (7), P30CA016672 (7), U01CA062502 (7), U01CA076576 (7), 2023 (6), P30CA043703 (6), U01CA062487 (6)